Telmisartan but not valsartan inhibits TGF-β-mediated accumulation of extracellular matrix via activation of PPARγ

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 28, Issue 5, 2008, Pages 543-548

  Yao, Ying ^a   Zou, Rong ^a   Liu, Xiaocheng ^a   Jiang, Jingjing ^a   Huang, Qian ^a   He, Yong ^a   Li, Meng ^a   Wang, Shixuan ^a   Zhou, Jianfeng ^a   Ma, Ding ^a   Xu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Glomerulosclerosis; Peroxisome proliferators activated receptor ; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TETRAZOLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; VALINE; VALSARTAN;

ANIMAL; ARTICLE; CELL CULTURE; EXTRACELLULAR MATRIX; FOCAL GLOMERULOSCLEROSIS; MESANGIUM CELL; METABOLISM; RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CELLS, CULTURED; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; MESANGIAL CELLS; PPAR GAMMA; RATS; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA; VALINE;

EID: 58449137236     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-008-0512-z     Document Type: Article

References (27)

1. A. Padiyar J. R. Sedor 2005 Genetic and genomic approaches to glomerulosclerosis Curr Mol Med 5 5 497 507
2. H. Makino 1992 Glomerular extracellular matrix in glomerulosclerosis by molecular biology Nippon Rinsho 50 12 3038 3045
3. S. Chen B. Jim F. N. Ziyadeh 2003 Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up Semin Nephrol 23 6 532 543
4. P. Libby J. Plutzky 2007 Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists Am J Cardiol 99 4A 27 40
5. A. M. Sharma B. Staels 2007 Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism J Clin Endocrinol Metab 92 2 386 395
6. M. Spears C. Mcsharry N. C. Thomson 2006 Peroxisome proliferator- activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease Clin Exp Allergy 36 12 1494 1504
7. K. Guyton R. Bond C. Reilly 2001 Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation J Leukoc Biol 69 4 631 638
8. F. Zheng A. Fornoni S. J. Elliot 2002 Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation Am J Physiol Renal Physiol 282 4 639 648
9. L. Tao H. R. Liu E. Gao 2003 Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia Circulation 108 22 2805 2811
10. P. Iglesias J. J. Diez 2006 Peroxisome proliferator-activated receptor gamma agonists in renal disease Eur J Endocrinol 154 5 613 621
11. S. C. Benson H. A. Pershadsingh C. I. Ho 2004 Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 43 5 993 1002
12. B. M. Forman P. Tontonoz J. Chen 1995 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 83 5 803 812
13. B. M. Brenner R. Beeuwkes 3rd 1978 The renal circulations Hosp Pract 13 7 35 46
14. T. H. Hostetter J. L. Olson H. G. Rennke 2001 Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation J Am Soc Nephrol 12 6 1315 1325
15. B. M. Brenner 1985 Nephron adaptation to renal injury or ablation Am J Physiol 249 3Pt2 324 337
16. B. M. Brenner 2002 Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 110 12 1753 1758
17. B. Li J. Yao K. Kawamura 2004 Real-time observation of glomerular hemodynamic changes in diabetic rats: effects of insulin and ARB Kidney Int 66 5 1939 1948
18. H. Kobori M. C. Prieto-carrasquero Y. Ozawa 2004 AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension Hypertension 43 5 1126 1132
19. M. Schupp J. Janke R. Clasen 2004 Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 17 2054 2057
20. I. Imayama T. Ichiki K. Inanaga 2006 Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma Cardiovasc Res 27 1 184 190
21. T. Yoshida S. Yamagishi K. Nakamura 2006 Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation Diabetologia 49 12 3094 3099
22. K. Sugimoto N. R. Qi L. Kazdova 2006 Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis Hypertension 47 5 1003 1009
23. T. W. Kurtz 2005 Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator Acta Diabetol 42 Suppl1 9 16
24. A. V. Cybulsky 2000 Growth factor pathways in proliferative glomerulonephritis Curr Opin Nephrol Hypertens 9 3 217 223
25. S. L. Morel-maroger P. D. Killen E. Chi 1984 The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis Lab Invest 51 2 181 192
26. F. Q. Dong H. Li W. M. Cai 2004 Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats Chin Med J (Engl) 117 7 1040 1044
27. S. Zafiriou S. R. Stanners S. Saad 2005 Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts J Am Soc Nephrol 16 3 638 645